Tag
The phase 3 SAFFRON trial demonstrated that osimertinib combined with savolitinib significantly improves progression-free and overall survival versus platinum-pemetrexed chemotherapy in advanced EGFR-mutated NSCLC harboring MET overexpressi
A cohort study reveals that open-source AI pathology models predicting EGFR mutations in lung adenocarcinoma demonstrate variable performance across ancestral groups, with notably lower accuracy in Asian patients (AUC 0.68) compared to Euro
This review evaluates the generalizability of AI pathology models in predicting EGFR mutations, highlighting significant performance variations across genetic ancestries and specimen types, and their role in clinical triage.
The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, wit
This study identifies activating EGFR L858R variants as the genetic basis for a syndrome featuring generalized acanthosis nigricans and lung nodules, highlighting the efficacy of EGFR inhibitors in treating both cutaneous and systemic manif
This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.
Limertinib demonstrates superior progression-free survival and a comparable safety profile to gefitinib, supporting its use as a first-line therapy in EGFR-mutated locally advanced or metastatic NSCLC.
